Z51.89: Encounter for other specified aftercare

Z51.89, encounter for other specified aftercare, is listed as a covered diagnosis in 4 Medicare billing and coding articles that apply to 33 HCPCS Level II codes, including J0897 (Injection, denosumab, 1 mg), Q5136 (Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg), Q5157 (Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar…). The articles come from 3 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.

HCPCS Level II codes with Z51.89 as a covered diagnosis

8 more codes are listed. See every code with payment by region in Caduvo.

Medicare policy articles listing Z51.89

• A52399: Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B); 10 Level II codes)
• A56748: Billing and Coding: White Cell Colony Stimulating Factors (Palmetto GBA (MAC - Part A, MAC - Part B); 16 Level II codes). LCD with the same title: L37176
• A53064: Billing and Coding: Outpatient Occupational Therapy (Palmetto GBA (MAC - Part A); 3 Level II codes). LCD with the same title: L34427
• A57311: Billing and Coding: Physical Therapy - Home Health (CGS Administrators, LLC (HHH MAC); 7 Level II codes). LCD with the same title: L33942

A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.

Other Z51 diagnoses (Encounter for other aftercare and medical care)

• Z51.81 — Encounter for therapeutic drug level monitoring
• Z51.11 — Encounter for antineoplastic chemotherapy
• Z51.12 — Encounter for antineoplastic immunotherapy

Frequently asked questions

Does Medicare cover Z51.89 (Encounter for other specified aftercare)?

Medicare covers items and services, not diagnoses. 4 Medicare billing and coding articles list Z51.89 as a covered diagnosis for 33 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.

Which HCPCS codes can be billed with ICD-10 Z51.89?

The Level II codes from the policies most specific to this diagnosis are J0897 (Injection, denosumab, 1 mg, 1 article); Q5136 (Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg, 1 article); Q5157 (Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar…, 1 article); Q5158 (Injection, denosumab-bnht (bomyntra/conexxence)…, 1 article); Q5159 (Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg, 1 article). Code choice depends on the item supplied; check each code's descriptor.

Which Medicare policy articles list Z51.89?

A52399 (Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars); A56748 (Billing and Coding: White Cell Colony Stimulating Factors); A53064 (Billing and Coding: Outpatient Occupational Therapy), and 1 more article.

What is ICD-10-CM code Z51.89?

Z51.89 is the ICD-10-CM code for encounter for other specified aftercare, in category Z51 (Encounter for other aftercare and medical care), chapter 22: Factors influencing health status and contact with health services.

Next steps

• Run a reimbursement report for a device billed under J0897
• Watch J0897 for fee, coverage and descriptor changes
• Build a full Medicare revenue model for J0897

Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.

Chapter 22: Factors influencing health status and contact with health services · All diagnoses · HCPCS lookup